The Influx Healthtech IPO concluded today, June 20th, 2025, with an astounding 201.35 times oversubscription! This signifies an incredible surge of investor interest in the healthcare-focused company.
The Rs 55.63 crore SME IPO saw a total of 81,71,71,200 shares bid for, far exceeding the 40,58,400 shares on offer. This overwhelming response breaks down as follows:
This incredible success follows strong subscription rates on the previous two days: 5.89 times on Day 1 and 25.47 times on Day 2.
While the morning saw a significant 39.58% GMP, the final GMP settled at a still-impressive 18.75%. This indicates strong investor confidence and the potential for significant listing gains.
Remember, the GMP is subject to market fluctuations and reflects investor sentiment.
Founded in September 2020, Influx Healthtech is a Contract Development and Manufacturing Organization (CDMO) specializing in healthcare. Operating three manufacturing units in Thane, the company produces a diverse range of products including tablets, capsules, powders, liquid orals, and softgels. The company showcased strong financial performance, with a 5% revenue increase and a 19% rise in profit after tax (PAT) between FY24 and FY25.
Rarever Financial Advisors Pvt Ltd acted as the book-running lead manager, while Maashitla Securities Private Limited served as the registrar. R K Stock Holding Private Limited was the market maker.
